Business Entheon Biomedical hands off DMT clinical study to Cybin Dimethyltryptamine continues to demonstrate tremendous therapeutic potential Rowan DunneJune 14, 2022
Cannabis Tetra Bio-Pharma enters Australia via new subsidiary acquisition Canadian company set to focus clinical trials down under, announces regulatory update Rowan DunneJune 6, 2022
Cannabis Inadequate testing for CBD contaminants raises industry concerns: Leafreport Many distributors are choosing not to test their products for microbes, pesticides and heavy metals Rowan DunneMay 26, 2022
Cannabis Consuming cannabis reduces fatigue symptoms: study Up to 37 per cent experienced positive side effects such as feeling active, energetic, "frisky" or productive Natalia Buendia CalvilloMay 9, 2022
Medical and Pharmaceutical Delic Labs granted permission to study psychedelics including LSD, MDMA The Vancouver-based research lab aims to increase understanding of the medical applications of psychedelic compounds Ryan GarnerApril 15, 2022
Medical and Pharmaceutical Psilocybin temporarily disrupts stages of the sleep cycle : study But whether or not the disruption helps with the substance's antidepressant properties still needs further research Natalia Buendia CalvilloApril 11, 2022
Business 92% of patients report improvements in chronic pain after using cannabis oil: Khiron study The study also found that seven out of ten patients did not suffer from adverse effects Natalia Buendia CalvilloApril 5, 2022
Business Numinus approved to study ayahuasca and San Pedro in Canada Used in sacred traditions for centuries, the firm says research will bring their medicinal benefits to a larger audience Natalia Buendia CalvilloMarch 9, 2022
News NFL awards $1M to research cannabis for pain management, concussion protection NFL players aren't allowed to participate in the research Kathryn TindaleFebruary 1, 2022
Driving Cannabis impairs driving performance longer than it feels: study But the results reinforce the view that laws based on blood-THC tests aren't supported by evidence Kathryn TindaleFebruary 1, 2022